消息面上，药捷安康此前宣布，拟配售2100万股新股份，每股配售价92.85港元，较1月13日H股收市价 113.2港元折让17.98%，所得款项净额1.9亿港元。其中，60%用于为其核心产品Tinengotinib在中国正在 进行单药治疗胆管癌(CCA)的临床试验以及核心产品的其他适应症的研发提供资金；约30%用于其他产 品的研发，包括TT-00973、TT-01488及其他分子；约10%用于营运资金及一般企业用途。 药捷安康-B(02617)再跌超10%，截至发稿，跌9.02%，报84.7港元，成交额1.17亿港元。 ...

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a decline of over 10%, currently trading at 84.7 HKD, with a transaction volume of 117 million HKD [1] Group 1: Stock Performance - Zymeworks Inc. shares fell by 9.02% to 84.7 HKD as of the latest report [1] - The stock has seen a significant drop following the announcement of a new share placement [1] Group 2: Share Placement Announcement - The company plans to place 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The net proceeds from the placement are expected to be 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]

Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping over 5% and more than 11% in the previous day, indicating market concerns regarding its recent equity placement and pricing strategy [1] Group 1: Stock Performance - As of the latest update, the stock is trading at 95.1 HKD with a trading volume of 82.17 million HKD [1] - The stock has seen a decline of over 5% in the current trading session following a previous drop of more than 11% [1] Group 2: Equity Placement - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib, specifically for its use in treating cholangiocarcinoma (CCA) in China [1] - About 30% of the proceeds will be directed towards the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% is intended for working capital and general corporate purposes [1]

Core Viewpoint - The stock of Zymeworks Inc. (02617) has experienced a significant decline, with a drop of over 5% and a previous plunge of more than 11% [1] Group 1: Stock Performance - As of the latest update, the stock is down 5%, trading at 95.1 HKD, with a trading volume of 82.17 million HKD [1] - The stock has seen a substantial decrease from its closing price of 113.2 HKD on January 13, reflecting a discount of approximately 17.98% on the new share placement price [1] Group 2: Share Placement Details - The company announced a placement of 2.1 million shares, which represents about 0.69% of the enlarged H shares and approximately 0.53% of the total issued shares [1] - The expected net proceeds from the placement are around 190 million HKD [1] Group 3: Use of Proceeds - Approximately 60% of the funds raised will be allocated to clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be utilized for working capital and general corporate purposes [1]

Group 1 - The core viewpoint of the article is that药捷安康-B (02617) experienced a decline of over 3%, specifically a drop of 3.71%, trading at 109 HKD with a transaction volume of 23.576 million HKD [1] - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] Group 2 - The expected net proceeds from the placement are approximately 190 million HKD, with around 60% allocated for funding clinical trials of the core product Tinengotinib for the treatment of cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% is designated for working capital and general corporate purposes [1]

Core Viewpoint - The company,药捷安康-B (02617), experienced a decline of over 3%, trading at 109 HKD with a transaction volume of 23.576 million HKD following the announcement of a share placement [1] Group 1: Share Placement Details - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] Group 2: Fund Utilization - The expected net proceeds from the placement are approximately 190 million HKD, with around 60% allocated for funding clinical trials of the core product Tinengotinib for the treatment of cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - Approximately 10% of the funds will be directed towards working capital and general corporate purposes [1]

Core Viewpoint - The company announced a placement agreement to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13, 2026 [1] Group 1: Placement Details - The placement shares represent about 0.69% of the enlarged issued H shares and approximately 0.53% of the total issued shares after completion [1] - The expected total gross proceeds from the placement are approximately HKD 195 million, with net proceeds estimated at around HKD 190 million [1] - The net issue price is approximately HKD 90.54 per share [1] Group 2: Use of Proceeds - Approximately 60% of the net proceeds will be allocated to fund clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be allocated for working capital and general corporate purposes [1]

Core Viewpoint - The company announced a placement agreement to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13, 2026 [1] Group 1: Placement Details - The placement shares represent about 0.69% of the enlarged issued H shares and approximately 0.53% of the total issued shares after completion [1] - The expected total gross proceeds from the placement are approximately HKD 195 million, with net proceeds estimated at HKD 190 million [1] - The net issue price is approximately HKD 90.54 per share [1] Group 2: Use of Proceeds - Approximately 60% of the net proceeds will be allocated to fund clinical trials for the core product Tinengotinib in the treatment of cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - Approximately 10% of the net proceeds will be allocated for working capital and general corporate purposes [1]

Core Viewpoint - The company,药捷安康-B (02617.HK), has announced a placement agreement with CITIC Securities to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13 [1] Group 1 - The placement shares represent about 0.70% of the existing issued H shares and 0.53% of the total issued shares as of the announcement date [1] - The expected total gross proceeds from the placement are approximately HKD 194.99 million, with net proceeds estimated at around HKD 190.14 million [1] Group 2 - The company plans to allocate approximately 60% of the net proceeds to fund clinical trials for its core product, Tinengotinib, in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the net proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國境內，或在刊發或派發本公告屬違法的任何其他 司法權區內刊發或派發。本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之 邀請或要約。 本公告不構成亦不屬於在美國境內或有關要約屬違法的任何其他司法權區出售證券的任何要約 或招攬購買或認購證券的一部分。本公告所述的本公司股份並無亦不會根據1933年美國證券法 （經修訂）（「美國證券法」）登記，且除非根據美國證券法登記規定進行登記或獲豁免遵守該等登 記規定，否則不得於美國境內提呈發售或出售。本公司無意根據美國證券法登記本公告內所指 之任何證券，或在美國境內進行證券之公開發售。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 根據一般授權配售新H股 配售事項 於2026年1月13日（交易時段後 ...